Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  SHENZHEN STOCK EXCHANGE  >  Huadong Medicine Co., Ltd    000963   CNE0000011S1

HUADONG MEDICINE CO., LTD

(000963)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Huadong Medicine : China Anti-Obesity Prescription Drugs Market Research Report 2019

share with twitter share with LinkedIn share with facebook
09/17/2019 | 12:29pm EDT

The China Anti-Obesity Prescription Drugs market is valued at USD 55.20 million in 2018 and is expected to reach USD 72.53 million by the end of 2025, growing at a CAGR of 3.90% between 2019 and 2025.

This report studies the Anti-Obesity Prescription Drugs development status and future trend in China, focuses on top players in China, also splits Anti-Obesity Prescription Drugs by type and by applications, to fully and deeply research and reveal the market general situation and future forecast.

The China Anti-Obesity Prescription Drugs market is valued at USD 55.20 million in 2018 and is expected to reach USD 72.53 million by the end of 2025, growing at a CAGR of 3.90% between 2019 and 2025.

Browse the report at - https://www.crystalmarketreport.com/china-anti-obesity-prescription-drugs-market-research-report-2018/

The major players in global market include -

Zhejiang Hisun

ZHIEN pharmaceutica

Lunan

Wanhan

Huadong Medicine

Roche

Other

Geographically, this report splits the China market into seven regions -

South China

East China

Southwest China

Northeast China

North China

Central China

Northwest China

Read full details of Table of contents - https://www.crystalmarketreport.com/china-anti-obesity-prescription-drugs-market-research-report-2018/toc

On the basis of product, the Anti-Obesity Prescription Drugs market is primarily split into -

OTC

Rx

On the basis on the end users/applications, this report covers -

Hospitals Pharmacies

Retail Pharmacies

E-commerce

Request free sample - https://www.crystalmarketreport.com/sample/211028

Table of Contents:

1 Anti-Obesity Prescription Drugs Overview 1

2 China Anti-Obesity Prescription Drugs Market Competition by Players/Manufacturers 22

3 China Anti-Obesity Prescription Drugs Sales and Revenue by Regions (2014-2019) 32

4 China Anti-Obesity Prescription Drugs Sales and Revenue by Type/ Product Category (2014-2019) 37

5 China Anti-Obesity Prescription Drugs Sales by Application (2014-2019) 42

6 Analysis of Anti-Obesity Prescription Drugs Industry Key Manufacturers 45

6.1 Zhejiang Hisun 45

6.2 ZHIEN pharmaceutica 47

6.3 Lunan 49

6.4 Wanhan 51

6.5 Huadong Medicine 53

6.6 Roche 55

7 Anti-Obesity Prescription Drugs Manufacturing Cost Analysis 57

8 Industrial Chain, Sourcing Strategy and Downstream Buyers 63

9 Marketing Strategy Analysis, Distributors/Traders 66

10 Factors Influencing 73

10.1 Price Trend of Key Industrial Raw Material 73

10.2 Imports & Exports 74

11 China Anti-Obesity Prescription Drugs Market Size (Sales and Revenue) Forecast (2020-2025) 80

12 Research Findings and Conclusion 86

13 Methodology and Data Source 87

Read full details of Table of contents - https://www.crystalmarketreport.com/china-anti-obesity-prescription-drugs-market-research-report-2018/toc

About Us:

Crystal Market Reports is a distributor of market research spanning 160 industries. Our extensive database consists of over 200,000 quality publications sourced from 400 plus publishers, this puts our research specialists in the unique position of been able to offer truly unbiased advice on what research provides the most valuable insights.

Media Contact

Company Name: Crystal Market Reports

Contact Person: Tom Sam

Email: sales@crystalmarketreport.com

Phone: 1-518-730-0564

Address:90 State Street, Suite 700

City: Albany

State: New York 12207

Country: United States

Website: www.crystalmarketreport.com/china-anti-obesity-prescription-drugs-market-research-report-2018

Source: www.abnewswire.com

.

(C) 2019 M2 COMMUNICATIONS, source M2 PressWIRE

Stocks mentioned in the article
ChangeLast1st jan.
HUADONG MEDICINE CO., LTD 0.98% 28.78 End-of-day quote.18.05%
ROCHE HOLDING AG -0.24% 329 Delayed Quote.7.22%
share with twitter share with LinkedIn share with facebook
Latest news on HUADONG MEDICINE CO., LTD
2019HUADONG MEDICINE : China Anti-Obesity Prescription Drugs Market Research Report ..
AQ
2018HUADONG MEDICINE : Sinclair Pharma agrees to potential offer from China's Huadon..
RE
2018HUADONG MEDICINE : Sinclair Pharma says Chinese firms given more time to make ta..
RE
2018Britain's Sinclair Pharma gets takeover interest from Chinese firms, shares s..
RE
More news
Financials
Sales 2020 37 395 M 5 344 M 5 344 M
Net income 2020 2 904 M 415 M 415 M
Net cash 2020 3 481 M 497 M 497 M
P/E ratio 2020 17,3x
Yield 2020 1,52%
Capitalization 50 360 M 7 201 M 7 196 M
EV / Sales 2019
EV / Sales 2020 1,25x
Nbr of Employees 12 118
Free-Float 41,2%
Chart HUADONG MEDICINE CO., LTD
Duration : Period :
Huadong Medicine Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HUADONG MEDICINE CO., LTD
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Average target price 29,10 CNY
Last Close Price 28,78 CNY
Spread / Highest target 44,5%
Spread / Average Target 1,13%
Spread / Lowest Target -29,8%
EPS Revisions
Managers
NameTitle
Liang Lü General Manager & Director
Bang Liang Li Chairman
Xin Hua Bai Chairman-Supervisory Board
Hong Lan Ma Chief Financial Officer
Cheng Wei Liu Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
HUADONG MEDICINE CO., LTD18.05%7 131
WALGREENS BOOTS ALLIANCE, INC.-28.27%34 220
MCKESSON CORPORATION1.86%22 840
CARDINAL HEALTH, INC.-0.57%14 272
WELCIA HOLDINGS CO., LTD.26.62%8 445
SINOPHARM GROUP CO., LTD.-30.69%8 189